Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020

Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*

by Matej Mikulic, last edited Aug 13, 2019
Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020 This statistic shows the percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017 to 2020. Nearly nine percent of executives stated they think drug spending reduction due to biosimilars will come into effect in 2017, while 25 percent think it will happen in 2020.
Show more

Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Generics and biosimilars
Generics and biosimilars

All Information
in one Presentation

Generics and biosimilars

Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Generics and biosimilars"
  • Global overview
  • Top companies
  • U.S. market
  • Patent expiration
  • Savings
  • Biosimilars
The most important statistics
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.